An immunotherapy drug that has shown potential in increasing survival rate to patients with different types of cervical cancer is Pembrolizumab, a monoclonal antibody that targets and binds on the PD-1 protein on the surface of T-cells, thus denying PD-1/PD-L1 interaction and allowing T-cell mediated destruction of cancer cells [31,32]. Here, PDCD1 is linked to cervical cancer.